BioSpace News Archive

Lucius Partners, LLC (“LP”), today announced the filing of two new patent applications to the USPTO by its portfolio company AerWave Medical, Inc.

C2N Diagnostics today announced the Annals of Clinical and Translational Neurology has published online a new study that further demonstrates the Amyloid Probability Score (APS), used in the company’s PrecivityAD® blood test to help healthcare providers better diagnose Alzheimer’s Disease (AD), is a reliable marker of brain amyloidosis among individuals aged 60 years and older with cognitive impairment (current Intended Use population).

Apex Labs Ltd. (APEX or the Company) is pleased to announce the completion of the first-ever take home microdose psilocybin clinical trial, meeting all endpoints over a two month period with no adverse events.

MediMergent announces the implementation of its digital clinical trials platform for the collection and analysis of RWD in a large multicenter study entitled EIMPRIS (Engaging Immuno-Protection Intervention Study) focused on the prevention of symptomatic SARS-CoV-2 infection in cancer patients.

Envision Pharma Group has appointed James “Jim” Streeter to the role of President of Technology, CTO and a member of the Executive Leadership Team.

SkinCure Oncology, provider of GentleCure™, a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy, the most advanced non-surgical technology for the treatment of common skin cancers, announced the elevation of two members of its leadership team to executive posts.

The Lupus Research Alliance announced the Lupus Accelerating Breakthroughs Consortium, a first-of-its-kind public-private partnership bringing people with lupus together in collaboration with the U.S. FDA, other federal agencies, medical societies, industry, academic clinical researchers and scientists to overcome scientific hurdles that are beyond the capacity of any single entity and to advance the development of urgently needed, personalized treatments for lupus.

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is pleased to announce it has engaged Montreal’s RobboDesign to revise and search engine optimize its website, to engage with critical limb ischemia “CLI” and peripheral arterial disease “PAD” patients, globally.

Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) today reported positive topline data from the company’s recently completed dose-escalation study of BDC-1001 in HER2-expressing solid tumors that support advancing into two Phase 2 studies.

Wren announced today the presentation of preclinical data for its first-in-class, oral inhibitors of α-synuclein oligomer generation demonstrating potent inhibition of both oligomer production and aggregate formation in cell and mouse models used for studying Parkinson’s disease progression.